Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Black Diamond Therapeutics I (BDTX)

95 + Investors. Track Smart Money conviction in BDTX. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↓ -2
Streak
2Q ▼
Buyers last Q
52%

Smart Money Signals — BDTX

Based on 97 hedge funds · latest filing: 2026 Q2 · updated quarterly

📉

Selling streak — 2 quarters in a row

last 6Q
For 2 consecutive quarters, more hedge funds reduced or closed their BDTX positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.
📊

High ownership — 94% of 3.0Y peak

94% of all-time peak
97 funds currently hold this stock — 94% of the 3.0-year high of 103 funds (reached 2025 Q4). Ownership is elevated but not yet at maximum concentration. Room to grow, but watch if the trend reverses.
📶

Steady growth — +4% more funds vs a year ago

fund count last 6Q
+4 new funds entered over the past year (+4% YoY). Gradual, steady growth in institutional ownership is generally a healthy signal — not a speculative rush, but consistent conviction.
🟡

Slight buying edge — 52% buying

64 buying59 selling
Last quarter: 64 funds bought or added vs 59 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.
📈

More new buyers each quarter (+12 vs last Q)

new funds entering per quarter
Funds opening a new BDTX position: 21 → 27 → 19 → 31. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.
🔒

47% of holders stayed for 2+ years

■ 47% conviction (2yr+) ■ 28% medium ■ 25% new
46 out of 97 hedge funds have held BDTX for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
➡️

Steady discovery — ~31 new funds/quarter

35 → 21 → 27 → 19 → 31 new funds/Q
New funds entering each quarter: 21 → 27 → 19 → 31. Consistent flow of new institutional buyers without clear acceleration or slowdown.
🏛️

Veteran-anchored — 59% veterans vs 28% newcomers

■ 59% veterans ■ 13% 1-2yr ■ 28% new
Entry-cohort mix of 101 holders: 60 (59%) are 2+ year veterans, 13 entered 1–2 years ago, and 28 (28%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
✅

Strong quality — 39% AUM from major funds

39% from top-100 AUM funds
36 of 95 holders rank in the top 100 by AUM, accounting for 39% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.
3.4
out of 10
Low Exit Risk
Exit risk score 3.4/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — BDTX

In 2026 Q2, 64 hedge funds were net buyers of BDTX (31 opened a new position, 33 added to an existing one), while 59 reduced or exited (26 trimmed, 33 sold completely) — a 52% buyer ratio, indicating a slight buying edge. Net selling has persisted for two consecutive quarters. 39% of total institutional value in BDTX is held by top-100 AUM funds, reflecting strong institutional quality. Net fund flow last quarter: -2 funds (more exits than new entries). Total institutional holders: 97.

Hedge Fund Ownership: BDTX

How many hedge funds hold BDTX — quarterly history vs. share price
Quarterly hedge fund ownership of BDTX vs. share price

Market Analysis: BDTX

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: BDTX

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Black Diamond Therapeutics I (BDTX) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much BDTX has moved relative to its sector benchmark (XLV) since the 2026 Q2 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End June 30, 2026 · 61d ago
BDTX
+20.5%
XLV
+8.7%

BDTX outperformed XLV by +11.8% since June 30, 2026.

Since 13F Filing Date August 14, 2026 · 16d ago
BDTX
+10.4%
XLV
+16.4%

Since the filing became public, BDTX outperformed XLV by -6.0% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

8 top-rated funds 0 high-conviction
Consensus
4.1
/ 10
breadth
×
Elite
0.2
/ 10
conviction
Hedge Fund Positioning: BDTX
95 + Investors

Track Smart Money conviction in BDTX. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q2) Prior (2026 Q1) Change
Funds Holding 95 99 -4.04%
13F Shares 36M 36M -2.55%
Total Value $54M $50M 7.35%
New Positions 31 19 +12
Increased Positions 31 31 -
Closed Positions 33 23 +10
Reduced Positions 25 32 -7
Total Calls 4 3 33.33%
Total Puts 2 2 -
PUT/CALL Ratio 0.5 0.67 Bullish

Statistics: BDTX

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q2)

95 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in BDTX. Verified SEC 13F-HR filings.

QUARTER:
Top 25 BDTX holders by conviction (% of portfolio weight) — 2026 Q2 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 NEA Management Company, LLC 0.52% 4,448,757 $8.2M
2 Defilade Capital Management, L.P. 0.41% 1,674,999 $3.1M
3 AWM Investment Company, Inc. 0.16% 1,000,000 $1.9M
4 Spark Investment Management LLC 0.06% 15,500 $29K
5 RB Capital Management, LLC 0.04% 100,000 $185K
6 DLK Investment Management, LLC 0.03% 16,215 $76K
7 Aster Capital Management (DIFC) Ltd 0.03% 49,171 $122K
8 Bridgeway Capital Management, LLC 0.03% 791,434 $1.5M
9 Renaissance Technologies LLC 0.00% 1,962,394 $3.6M
10 Ritholtz Wealth Management 0.00% 178,479 $330K
11 Beacon Capital Management, LLC 0.00% 15,615 $29K
12 Connor, Clark & Lunn Investment Management Ltd. 0.00% 1,092,885 $2.0M
13 O'shaughnessy Asset Management, LLC 0.00% 288,871 $534K
14 Empowered Funds, LLC 0.00% 248,134 $459K
15 Graham Capital Management, L.P. 0.00% 54,232 $100K
16 Panagora Asset Management Inc 0.00% 295,172 $546K
17 Marshall Wace, LLP 0.00% 896,602 $1.7M
18 Balyasny Asset Management L.P. 0.00% 542,172 $1.0M
19 Quadrature Capital Ltd 0.00% 76,706 $142K
20 XTX Topco Ltd 0.00% 44,301 $82K
21 China Universal Asset Management Co., Ltd. 0.00% 9,120 $17K
22 Kathmere Capital Management, LLC 0.00% 10,248 $19K
23 EFG International AG 0.00% 27,000 $50K
24 Diversified Trust Co 0.00% 18,860 $35K
25 Toronto Dominion Bank 0.00% 214,000 $396K
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Black Diamond Therapeutics I (BDTX)

What does the Smart Money Trend signal show for BDTX?

Selling streak — 2 quarters in a row: For 2 consecutive quarters, more hedge funds reduced or closed their BDTX positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

What is the institutional breadth score for BDTX?

Slight buying edge — 52% buying: Last quarter: 64 funds bought or added vs 59 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for BDTX holders?

Strong quality — 39% AUM from major funds: 36 of 95 holders rank in the top 100 by AUM, accounting for 39% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held BDTX?

47% of holders stayed for 2+ years: 46 out of 97 hedge funds have held BDTX for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Black Diamond Therapeutics I (BDTX) following the 2026 Q2 hedge fund 13F filings?

As of today, BDTX has moved +10.4% since the 2026 Q2 13F filing date (August 14, 2026), compared to +16.4% for the XLV sector ETF — an outperformance of -6.0%. Since the quarter end (June 30, 2026), BDTX has gained +20.5% vs +8.7% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →